Related Experiment Video

Updated: Aug 31, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer

Abhijit Mazumdar1, William M Tahaney1,2, Jamal L Hill1

  • 1Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer Prevention Research (Philadelphia, Pa.)
|August 18, 2022
PubMed
Abstract

Insights

Everolimus, an mTOR inhibitor, was found to delay mammary tumor development in mice. This suggests mTOR inhibitors could be valuable for preventing estrogen receptor-negative and triple-negative breast cancer in people.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Estrogen receptor-negative (ER-) and triple-negative breast cancer (TNBC) are aggressive subtypes with limited targeted prevention strategies.
  • The mechanistic target of rapamycin (mTOR) pathway is implicated in breast cancer development and progression.

Purpose of the Study:

  • To investigate the efficacy of everolimus, an mTOR inhibitor, in preventing mammary tumor formation.
  • To evaluate the potential of mTOR inhibitors for the prevention of specific breast cancer subtypes.

Main Methods:

  • Utilized multiple mouse models of mammary tumor formation.
  • Administered everolimus to assess its impact on tumor onset and development.

Main Results:

  • Everolimus significantly delayed the formation of mammary tumors across various tested mouse models.
  • The drug demonstrated preventative effects in models relevant to ER-negative and TNBC.

Conclusions:

  • mTOR inhibitors, exemplified by everolimus, show promise as a preventative strategy for ER-negative and triple-negative breast cancer.
  • These findings support further investigation into mTOR inhibitors for human breast cancer prevention.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.3K
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

10.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K